A Molecular Biologist by training, Sabrina is an entrepreneur with over 15 years of experience in nonclinical drug development, regulatory affairs, and business development in the global biopharmaceutical industry. Sabrina received her first exposure in orphan drug regulations while working for the ex-Director of the Office of Orphan Products, discovering her passion for the rare disease space, and since, along with her team, has supported well over 50 unique orphan-drug programs and hundreds of regulatory interactions and submissions. Previously, Sabrina led and coordinated business and corporate development strategies at rare disease consulting firms and held Business Development and Director-level roles for global preclinical Contract Research Organizations. She has successfully channeled a passion for both business and rare diseases into building RareMoon, a global orphan-drug regulatory services firm focused on translating science into concise regulatory documents in preparation for key clinical trials. In addition to leading the strategic team at RareMoon, Sabrina advises on worldwide regulatory submissions and interactions including Orphan-Drug Designations, Breakthrough Therapy Designations, Fast Track Designations, Rare Pediatric Designations, Priority Review Vouchers, PRIME, and FDA and EMA meetings. Her vision and her insistence on holding true to core values, integrity, and commitment, are reflected in the company’s mission and track record of 100%. Maintaining that commitment and piloting orphan programs to regulatory milestones, ultimately, driving successful programs.